NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk
Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk

NCT07007208

RecruitingPhase 2

Sponsor: University Hospital, Toulouse

Conditions: Alzheimer Disease

Interventions: a positon emission tomography (PET) exam, MRI Contrast, oculometry assessment, cognitive exams

Countries: France

Alzheimer's disease (AD) is characterized by a long-lasting silent phase. Among initial events, emergence of tau pathology in locus coeruleus (LC) brainstem nucleus, well before the one observed in medial temporal cortex, is highly relevant. LC integrity and function can be assessed in vivo with MRI and pupil measures. The current research proposes to evaluate these LC markers in an aged healthy cohort (n=100, with half APOE4 positive) and to relate these markers with cerebral tau pathology, AD risk and cognitive function.

Eligibility overview

Sex: ALL

Age: 60 Years to 100 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Participant in the INSPIRE-T cohort
* Normal cognitive assessment
* MMSE score ≥ 27 out of 30 (Mini-Mental State Examination)
* Normal visual abilities (in corrected or uncorrected vision)
* Normal motor skills

Exclusion Criteria:

* Subjects with a contraindication to MRI exam
* Subjects with a known allergic reaction to the PET radiopharmaceutical (\[18F\] Flortaucipir) or any of its excipients
* Subjects with an ophthalmological pathology making oculometric measurements difficult
* Subjects with a neurodegenerative condition or a history of cerebral ischemia
* Subjects with a psychiatric disorder and a PHQ-9 score \> 10 or under treatment with NRI
Locations (1)
  • Toulouse, France